BioMarin to Use Myriad's HRD Test as CDx for Drug Candidate | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics today announced a research collaboration for use of the company's homologous recombination deficiency test to identify tumor types that may serve as targets for BioMarin's investigational drug candidate BMN-673.

Myriad's test detects tumors that may be susceptible to DNA-damaging drugs because they no longer can repair double-stranded DNA breaks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: transcriptomic analysis of the Venus flytrap, SMASH approach for CNV analysis, and more.

A Caltech professor wins the Millennium Technology Prize that lauds technological advances that improve human life.

San Diego's biotech scene has a dearth of executives who are women, Stat News reports.

Some 90 percent of respondents to a Nature survey say there is a research reproducibility crisis.